Citations

Clear

4610 citation(s) found for "Lu, Brian".

A Polymorphism in the Complement ComponentC1qACorrelates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Racila, Emilian , Link, Brian K. , Weng, Wen‐Kai , Ansell, Stephen M. , Maurer, Matthew J. , Dahle, Christopher E., Halwani, Ahmad , Levy, Ronald , Witzig, Thomas E. , Huang, Jian , Weiner, George J. , Maurer, Matthew , Link, Brian K

Mayo Clinic

Clinical Cancer Research | October 16, 2008 | Volume: 14 | Issue: 20 | Pages: 6697-6703

10.1158/1078-0432.ccr-08-0745 | PMID 18927313 Get It

AbstractPurpose: Complement may play a role in the clinical response to rituximab and other monoclonal antibody–based therapies of cancer. The purpose of this study was to explore the relationship between the C1qA[276] polymorphism and the clinical response to rituximab in patients with follicular lymphoma.Experimental Design: Genotyping for C1qA[276A/G] was done in 133 subjects with follicular lymphoma treated with single-agent rituximab, and correlation with clinical response was done using Cox regression analysis.Results: Prolonged remission was observed among subjects that responded clinically to rituximab therapy and were carriers of the A allele compared with homozygous G subjects. Homozygous G subjects had a time to progression of 282 days, whereas A-allele carriers had a time to progression of 708 days [hazard ratio, (HR), 2.5; 95% confidence interval (95% CI), 2.0-3.1; P = 0.02]. Among subjects who achieved complete remission, homozygous G subjects had a time to progression of 250 days, whereas A-allele carriers had a time to progression of 1,118 days (HR, 4.5; 95% CI, 4.1-4.8, P = 0.04). The difference persisted after controlling for CD32 and CD16 polymorphisms. In patients who responded to rituximab used as first-line agent, a linear trend was observed among the C1qA[276] genotypes, with homozygous A subjects achieving complete response at a higher rate compared with heterozygous or homozygous G subjects.Conclusions: Our findings indicate that polymorphisms in the C1qA gene may affect the clinical response and duration of response to rituximab therapy of follicular lymphoma. These results could have direct implications on designing antibodies with improved efficiency and enhance our understanding of the role of complement in monoclonal antibody therapy.
Renal medullary 11β-hydroxysteroid dehydrogenase type 1 in Dahl salt-sensitive hypertension
Usa, Kristie , Netzel, Brian C., Liang, Mingyu , Liu, Yong , Singh, Ravinder J.

Mayo Clinic

Physiological Genomics | October 1, 2008 | Volume: 36 | Issue: 1 | Pages: 52-58

10.1152/physiolgenomics.90283.2008 | PMID 18826995 Get It

The Dahl salt-sensitive rat is a widely used model of human salt-sensitive forms of hypertension. The kidney plays an important role in the pathogenesis of Dahl salt-sensitive hypertension, but the molecular mechanisms involved remain a subject of intensive investigation. Gene expression profiling studies suggested that 11β-hydroxysteroid dehydrogenase type 1 might be dysregulated in the renal medulla of Dahl salt-sensitive rats. Additional analysis confirmed that renal medullary expression of 11β-hydroxysteroid dehydrogenase type 1 was downregulated by a high-salt diet in SS-13BN rats, a consomic rat strain with reduced blood pressure salt sensitivity, but not in Dahl salt-sensitive rats. 11β-Hydroxysteroid dehydrogenase type 1 is known to convert inactive 11-dehydrocorticosterone to active corticosterone. The urinary corticosterone/11-dehydrocorticosterone ratio as well as urinary excretion of corticosterone was higher in Dahl salt-sensitive rats than in SS-13BN rats. Knockdown of renal medullary 11β-hydroxysteroid dehydrogenase type 1 with small-interfering RNA attenuated the early phase of salt-induced hypertension in Dahl salt-sensitive rats and reduced urinary excretion of corticosterone. Knockdown of 11β-hydroxysteroid dehydrogenase type 1 did not affect blood pressure in SS-13BN rats. Long-term attenuation of salt-induced hypertension was achieved with small hairpin RNA targeting renal medullary 11β-hydroxysteroid dehydrogenase type 1. In summary, we have demonstrated that suppression of 11β-hydroxysteroid dehydrogenase type 1 expression in the renal medulla attenuates salt-induced hypertension in Dahl salt-sensitive rats.
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
Johnson, David C. , Corthals, Sophie L., Ramos, Christine, Hoering, Antje , Cocks, Kim , Dickens, Nicholas J. , Haessler, Jeff, Goldschmidt, H., Child, J. Anthony, Bell, Sue , Jackson, Graham , Baris, Dalsu , Rajkumar, S. Vincent , Davies, Faith E. , Durie, Brian G.M. , Crowley, John, Sonneveld, Pieter , Ness, Brian Van, Morgan, Gareth J. , Rajkumar, S Vincent , Davies, Faith E , Morgan, Gareth J

Mayo Clinic

Blood | September 20, 2008 | Volume: 112 | Issue: 13 | Pages: 4924-4934

10.1182/blood-2008-02-140434 | PMID 18805967 Get It

AbstractA venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide. The susceptibility to developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic and environmental factors. To test genetic variation associated with treatment related VTE in patient peripheral blood DNA, we used a custom-built molecular inversion probe (MIP)–based single nucleotide polymorphism (SNP) chip containing 3404 SNPs. SNPs on the chip were selected in “functional regions” within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and side effects associated with myeloma therapy. Patients and controls were taken from 3 large clinical trials: Medical Research Council (MRC) Myeloma IX, Hovon-50, and Eastern Cooperative Oncology Group (ECOG) EA100, which compared conventional treatments with thalidomide in patients with myeloma. Our analysis showed that the set of SNPs associated with thalidomide-related VTE were enriched in genes and pathways important in drug transport/metabolism, DNA repair, and cytokine balance. The effects of the SNPs associated with thalidomide-related VTE may be functional at the level of the tumor cell, the tumor-related microenvironment, and the endothelium. The clinical trials described in this paper have been registered as follows: MRC Myeloma IX: ISRCTN68454111; Hovon-50: NCT00028886; and ECOG EA100: NCT00033332.
Differential diagnosis of suspected multiple sclerosis: a consensus approach
Miller, DH, Weinshenker, BG, Filippi, Massimo , Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, Michael , Johnson, RT, Kappos, Ludwig , Lublin, FD, McFarland, HF, Montalbán, Xavier , Panitch, Hillel, Richert, J, Reingold, Stephen C. , Polman, C.H., Weinshenker, Brian G. , Sl, Galetta, Kira, Jun‐ichi , Weinshenker, Brian G , Filippi, Massimo

Mayo Clinic

Multiple Sclerosis Journal | September 19, 2008 | Volume: 14 | Issue: 9 | Pages: 1157-1174

10.1177/1352458508096878 | PMID 18805839 Get It

Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings. A systematic process for exclusion of alternative diagnoses has not been defined. An International Panel of MS experts developed consensus perspectives on MS differential diagnosis. Methods Using available literature and consensus, we developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases. Results We present recommendations for 1) clinical and paraclinical red flags suggesting alternative diagnoses to MS; 2) more precise definition of “clinically isolated syndromes” (CIS), often the first presentations of MS or its alternatives; 3) algorithms for diagnosis of three common CISs related to MS in the optic nerves, brainstem, and spinal cord; and 4) a classification scheme and diagnosis criteria for idiopathic inflammatory demyelinating disorders of the central nervous system. Conclusions Differential diagnosis leading to MS or alternatives is complex and a strong evidence base is lacking. Consensus-determined guidelines provide a practical path for diagnosis and will be useful for the non-MS specialist neurologist. Recommendations are made for future research to validate and support these guidelines. Guidance on the differential diagnosis process when MS is under consideration will enhance diagnostic accuracy and precision.
The C ombined Approach to L ysis Utilizing E ptifibatide a nd r t-PA in Acute Ischemic Stroke
Pancioli, Arthur , Brott, Thomas G. , Tomsick, Thomas A. , Bean, Judy A., Zoppo, Gregory del, Kleindorfer, Dawn , Woo, Daniel , Khatri, Pooja , Castaldo, John , Frey, James L., Gebel, James, Kidwell, Chelsea S., Kwiatkowski, Thomas , Libman, Richard , Mackenzie, Richard S., Starkman, Sidney , Thurman, R. Jason, Jauch, Edward C. , Liebeskind, David S. , Meurer, William J. , Buck, Brian , Broderick, Joseph P. , Khoury, Jane , Kasner, Scott Eric , Scott, Phillip , Liebeskind, David S. , Buck, Brian H , Khatri, Pooja

Mayo Clinic

Stroke | September 5, 2008 | Volume: 39 | Issue: 12 | Pages: 3268-3276

10.1161/strokeaha.108.517656 | PMID 18772447 Get It

Background and Purpose— Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The c ombined approach to l ysis utilizing e ptifibatide a nd r ecombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination. Methods— The CLEAR trial was a National Institutes of Health/National Institute of Neurological Disorders and Stroke–funded multicenter, double-blind, randomized, dose-escalation and safety study. Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg). The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours. Secondary analyses were performed regarding clinical efficacy. Results— Ninety-four patients (40 in tier 1 and 54 in tier 2) were enrolled. The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 ( P =0.01 for NIHSS score). Fifty-two (75%) of the combination treatment group and 24 (96%) of the standard treatment group had a baseline modified Rankin scale score of 0 ( P =0.04). There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA–only arm ( P =0.17). During randomization in tier 2, a review by the independent data safety monitoring board demonstrated that the safety profile of combination therapy at the tier 2 doses was such that further enrollment was statistically unlikely to indicate inadequate safety for the combination treatment group, the ultimate outcome of the study. Thus, the study was halted. There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group. Conclusions— The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke.
Vessel-Specific Toll-Like Receptor Profiles in Human Medium and Large Arteries
Pryshchep, Olga, Ma-Krupa, Wei, Younge, Brian R., Goronzy, Jörg J. , Weyand, Cornelia M. , Goronzy, Jorg

Mayo Clinic

Circulation | September 3, 2008 | Volume: 118 | Issue: 12 | Pages: 1276-1284

10.1161/circulationaha.108.789172 | PMID 18765390 Get It

Background— Inflammatory vasculopathies, ranging from the vasculitides (Takayasu arteritis, giant cell arteritis, and polyarteritis nodosa) to atherosclerosis, display remarkable target tissue tropisms for selected vascular beds. Molecular mechanisms directing wall inflammation to restricted anatomic sites within the vascular tree are not understood. We have examined the ability of 6 different human macrovessels (aorta and subclavian, carotid, mesenteric, iliac, and temporal arteries) to initiate innate and adaptive immune responses by comparing pathogen-sensing and T-cell–stimulatory capacities. Methods and Results— Gene expression analysis for pathogen-sensing Toll-like receptors (TLRs) 1 to 9 showed vessel-specific profiles, with TLR2 and TLR4 ubiquitously present, TLR7 and TLR9 infrequent, and TLR1, TLR3, TLR5, TLR6, and TLR8 expressed in selective patterns. Experiments with vessel walls stripped of the intimal or adventitial layer identified dendritic cells at the media-adventitia junction as the dominant pathogen sensors. In human artery–severe combined immunodeficiency (SCID) mouse chimeras, adoptively transferred human T cells initiated vessel wall inflammation if wall-embedded dendritic cells were conditioned with TLR ligands. Wall-infiltrating T cells displayed vessel-specific activation profiles with differential production of CD40L, lymphotoxin-α, and interferon-γ. Vascular bed–specific TLR fingerprints were functionally relevant, as exemplified by differential responsiveness of iliac and subclavian vessels to TLR5 but not TLR4 ligands. Conclusions— Populated by indigenous dendritic cells, medium and large human arteries have immune-sensing and T-cell–stimulatory functions. Each vessel in the macrovascular tree exhibits a distinct TLR profile and supports selective T-cell responses, imposing vessel-specific risk for inflammatory vasculopathies.
Advanced Glycation End Products Accumulate in Vascular Smooth Muscle and Modify Vascular but Not Ventricular Properties in Elderly Hypertensive Canines
Shapiro, Brian P. , Owan, Theophilus , Mohammed, Selma F. , Meyer, Donna , Redfield, Margaret M. , Mills, Lisa D. , Schalkwijk, Casper G.

Mayo Clinic

Circulation | August 19, 2008 | Volume: 118 | Issue: 10 | Pages: 1002-1010

10.1161/circulationaha.108.777326 | PMID 18711013 Get It

Background— Advanced glycation end products (AGEs) are believed to increase left ventricular (LV) and vascular stiffness, in part via cross-linking proteins. We determined whether and where AGEs were increased in elderly hypertensive nondiabetic dogs and whether an AGE cross-link breaker (ALT-711) improved vascular or ventricular function. Methods and Results— Elderly dogs with experimental hypertension (old hypertensives [OH]) were randomized to receive ALT-711 (OH+ALT group; n=11; 1 mg/kg PO) or not (OH group; n=11) for 8 weeks. Conscious blood pressure measurements (weekly), echocardiography (week 8), and anesthetized study (week 8) with LV pressure–volume analysis and aortic pressure–dimension and pressure–flow assessment over a range of preloads and afterloads were performed. In LV and aorta from OH, OH+ALT, and young normal dogs, AGE content (immunohistochemistry and Western analysis for N ε -(carboxymethyl)lysine [CML]) was assessed. Aortic CML content was markedly increased in OH and OH+ALT dogs compared with young normal dogs. CML was localized to aortic and aortic vasa vasorum smooth muscle but not to collagen or elastin. CML was essentially undetectable in young normal, OH, or OH+ALT myocardium but was visible in large vessels in the LV. ALT-711 therapy was associated with lower blood pressure and pulse pressure, decreased systemic vascular resistance, increased aortic distensibility and arterial compliance, and, notably, significant aortic dilatation. Neither LV systolic nor diastolic function was different in OH+ALT versus OH dogs. Conclusions— In elderly hypertensive canines, AGE accumulation and AGE cross-link breaker effects were confined to the vasculature without evidence of myocardial accumulation or effects. The lack of AGE accumulation in collagen-rich areas suggests that the striking vascular effects may be mediated by mechanisms other than collagen cross-linking.
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Lee, Stephanie J. , Kukreja, Manisha, Szer, Jeff , Arora, Mukta , Woolfrey, Ann E. , Cervantes, Francisco , Halter, Joerg , Marks, David I. , Olavarría, Eduardo, Stadtmauer, Edward A. , Abecasis, Manuel, Gupta, Vikas , Khoury, H. Jean, Hale, Gregory A., Rizzieri, David A. , Antin, Joseph H. , Bolwell, Brian J., Carabasi, Matthew, Copelan, Edward A. , İlhan, Osman , Litzow, Mark R. , Schouten, H, Zander, Axel R., Horowitz, Mary M. , Halter, Jörg , Wang, Tao , Giralt, Sergio , Champlin, Richard E. , Gale, Robert Peter , Keating, Armand , McCarthy, Philip L. , George, Biju , Liesveld, Jane L. , Maziarz, Richard Thomas , Gupta, Vikas , Lee, Stephanie J

Mayo Clinic

Blood | July 30, 2008 | Volume: 112 | Issue: 8 | Pages: 3500-3507

10.1182/blood-2008-02-141689 | PMID 18664621 Get It

AbstractImatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM+) and 900 subjects who did not receive IM before HCT (IM−) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatment-related mortality, relapse, leukemia-free survival, or survival. Acute graft-versus-host disease rates were similar between IM+ and IM− groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.
IC‐P2‐154: Patterns of regional change over time in the syndromic variants of frontotemporal dementia and Alzheimer's disease
Whitwell, Jennifer L. , Josephs, Keith A. , Senjem, Matthew L. , Przybelski, Scott A. , Weigand, Stephen D. , Gregg, Brian E., Hannon, Mike, Petersen, Ronald C. , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R. , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2008.05.2608 Get It

O3‐06–06: Patterns of regional change over time in the syndromic variants of frontotemporal dementia and Alzheimer's disease
Whitwell, Jennifer L. , Josephs, Keith A. , Senjem, Matthew L. , Przybelski, Scott A. , Weigand, Stephen D. , Gregg, Brian E., Hannon, Mike, Petersen, Ronald C. , Knopman, David S. , Boeve, Bradley F. , Jack, Clifford R. , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2008.05.455 Get It